PureTech Health (PRTC) to Release Earnings on Wednesday

PureTech Health (NASDAQ:PRTC) is expected to release its H2 2025 results before the market opens on Wednesday, April 29th. Analysts expect PureTech Health to post earnings of ($1.94) per share and revenue of $1.90 million for the quarter. Interested persons can find conference call details on the company’s upcoming H2 2025 earning report page for the latest details on the call scheduled for Wednesday, April 29, 2026 at 9:00 AM ET.

PureTech Health Trading Up 1.0%

PRTC stock opened at $17.12 on Monday. PureTech Health has a twelve month low of $14.50 and a twelve month high of $19.92. The firm’s fifty day simple moving average is $16.87 and its two-hundred day simple moving average is $17.25.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of PureTech Health in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently raised its position in PureTech Health stock. Pentwater Capital Management LP lifted its stake in PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) by 50.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 75,000 shares of the company’s stock after purchasing an additional 25,000 shares during the period. Pentwater Capital Management LP owned about 0.31% of PureTech Health worth $1,388,000 at the end of the most recent quarter. 0.04% of the stock is currently owned by institutional investors and hedge funds.

PureTech Health Company Profile

PureTech Health (NASDAQ: PRTC) is a clinical-stage biotherapeutics company focused on creating and developing first-in-class medicines across immunology, inflammation, oncology and neuroscience. The company operates through a model of incubating programs in-house and advancing selected assets into independent, value-creating entities. Its internal pipeline includes multiple clinical and preclinical candidates addressing fibrotic diseases, solid tumors and rare genetic disorders.

PureTech’s proprietary platform technologies span modalities such as monoclonal antibodies, small molecules and cell-based therapies.